 "Pharmaceutical products in bottles")
Shares of Divis Laboratories tanked 20% to Rs 635, also its 52-week low on BSE in early morning trade, after the company said US drug regulator issued an import alert on the company’s Visakhapatnam unit-II.
“The United States Food and Drug Administration (USFDA) have issued an Import Alert 66-40 on 20th March 2017 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh,” Divis Laboratories said in a statement.
“The agency has exempted the 10 active pharmaceutical ingredients (APIs) namely Levetiracetam, Gabapentin, Lamotrigine , Capecitabine, Naproxen Sodium, Raltegravir potassium, Atovaquone, Chloropurine , BOC core succinate and
“The United States Food and Drug Administration (USFDA) have issued an Import Alert 66-40 on 20th March 2017 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh,” Divis Laboratories said in a statement.
“The agency has exempted the 10 active pharmaceutical ingredients (APIs) namely Levetiracetam, Gabapentin, Lamotrigine , Capecitabine, Naproxen Sodium, Raltegravir potassium, Atovaquone, Chloropurine , BOC core succinate and
